Ocular Involvement in Systemic Lupus Erythematosus Patients: a Paradigm Shift Based on the Experience of a Tertiary Referral Center

Detalhes bibliográficos
Autor(a) principal: Dias-Santos, A
Data de Publicação: 2020
Outros Autores: Ferreira, J, Pinheiro, S, Cunha, JP, Alves, M, Papoila, AL, Moraes-Fontes, MF, Proença, R
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.17/3915
Resumo: Objective: To evaluate ocular involvement in a cohort of systemic lupus erythematosus (SLE) patients of a tertiary referral center and to compare the results with the existing literature. Methods: Patients underwent a complete ophthalmological evaluation, including visual acuity, slit-lamp examination, fluorescein staining, Schirmer-I test, Goldmann applanation tonometry, fundoscopy, 10-2 automated threshold visual fields, fundus autofluorescence and spectral-domain optical coherence tomography to screen for hydroxychloroquine (HCQ) macular toxicity. Results: A total of 161 patients (16 men and 145 women) were enrolled in this study. The mean age was 47.6 years and the mean disease duration was 11.5 years. Fifty patients (31.1%) had at least one ocular manifestation of SLE. The most frequent manifestation was dry eye syndrome (12.4%), immediately followed by cataracts (11.2%) and HCQ macular toxicity (11.2%). Among patients with HCQ maculopathy, two presented with an atypical spectral-domain optical coherence tomography pattern. Five patients (3.1%) presented with glaucoma, two patients (1.2%) presented with SLE retinopathy while only one presented with lupus choroidopathy (0.6%). Conclusions: Compared with previous studies, we conclude there has been a significant reduction in disease-related ocular complications, particularly those associated with poor systemic disease control. On the other hand, drug and age-related complications are assuming a prominent role in the ophthalmic care of these patients.
id RCAP_0e5973bc6ff4e4f7cc780a0bfb4ca2db
oai_identifier_str oai:repositorio.chlc.min-saude.pt:10400.17/3915
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Ocular Involvement in Systemic Lupus Erythematosus Patients: a Paradigm Shift Based on the Experience of a Tertiary Referral CenterCHLC OFTHSAC DAUTOIMHCC DAUTOIMCHLC CINVAdultFemaleMaleHumansAntirheumatic Agents / adverse effectsDrug-Related Side Effects and Adverse Reactions / diagnosisDrug-Related Side Effects and Adverse Reactions / etiologyEye Diseases / diagnosisEye Diseases / etiologyHydroxychloroquine / adverse effectsLupus Erythematosus, Systemic / complications*Lupus Erythematosus, Systemic / diagnosisMiddle AgedPrevalenceProspective StudiesRetinal Diseases / chemically inducedRetinal Diseases / diagnosisTertiary Care CentersTomography, Optical CoherenceVisual AcuityObjective: To evaluate ocular involvement in a cohort of systemic lupus erythematosus (SLE) patients of a tertiary referral center and to compare the results with the existing literature. Methods: Patients underwent a complete ophthalmological evaluation, including visual acuity, slit-lamp examination, fluorescein staining, Schirmer-I test, Goldmann applanation tonometry, fundoscopy, 10-2 automated threshold visual fields, fundus autofluorescence and spectral-domain optical coherence tomography to screen for hydroxychloroquine (HCQ) macular toxicity. Results: A total of 161 patients (16 men and 145 women) were enrolled in this study. The mean age was 47.6 years and the mean disease duration was 11.5 years. Fifty patients (31.1%) had at least one ocular manifestation of SLE. The most frequent manifestation was dry eye syndrome (12.4%), immediately followed by cataracts (11.2%) and HCQ macular toxicity (11.2%). Among patients with HCQ maculopathy, two presented with an atypical spectral-domain optical coherence tomography pattern. Five patients (3.1%) presented with glaucoma, two patients (1.2%) presented with SLE retinopathy while only one presented with lupus choroidopathy (0.6%). Conclusions: Compared with previous studies, we conclude there has been a significant reduction in disease-related ocular complications, particularly those associated with poor systemic disease control. On the other hand, drug and age-related complications are assuming a prominent role in the ophthalmic care of these patients.SageRepositório do Centro Hospitalar Universitário de Lisboa Central, EPEDias-Santos, AFerreira, JPinheiro, SCunha, JPAlves, MPapoila, ALMoraes-Fontes, MFProença, R2021-11-23T15:12:01Z2020-032020-03-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.17/3915engLupus. 2020 Mar;29(3):283-289.10.1177/0961203320903080.info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-03-10T09:44:37Zoai:repositorio.chlc.min-saude.pt:10400.17/3915Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T17:21:13.558873Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Ocular Involvement in Systemic Lupus Erythematosus Patients: a Paradigm Shift Based on the Experience of a Tertiary Referral Center
title Ocular Involvement in Systemic Lupus Erythematosus Patients: a Paradigm Shift Based on the Experience of a Tertiary Referral Center
spellingShingle Ocular Involvement in Systemic Lupus Erythematosus Patients: a Paradigm Shift Based on the Experience of a Tertiary Referral Center
Dias-Santos, A
CHLC OFT
HSAC DAUTOIM
HCC DAUTOIM
CHLC CINV
Adult
Female
Male
Humans
Antirheumatic Agents / adverse effects
Drug-Related Side Effects and Adverse Reactions / diagnosis
Drug-Related Side Effects and Adverse Reactions / etiology
Eye Diseases / diagnosis
Eye Diseases / etiology
Hydroxychloroquine / adverse effects
Lupus Erythematosus, Systemic / complications*
Lupus Erythematosus, Systemic / diagnosis
Middle Aged
Prevalence
Prospective Studies
Retinal Diseases / chemically induced
Retinal Diseases / diagnosis
Tertiary Care Centers
Tomography, Optical Coherence
Visual Acuity
title_short Ocular Involvement in Systemic Lupus Erythematosus Patients: a Paradigm Shift Based on the Experience of a Tertiary Referral Center
title_full Ocular Involvement in Systemic Lupus Erythematosus Patients: a Paradigm Shift Based on the Experience of a Tertiary Referral Center
title_fullStr Ocular Involvement in Systemic Lupus Erythematosus Patients: a Paradigm Shift Based on the Experience of a Tertiary Referral Center
title_full_unstemmed Ocular Involvement in Systemic Lupus Erythematosus Patients: a Paradigm Shift Based on the Experience of a Tertiary Referral Center
title_sort Ocular Involvement in Systemic Lupus Erythematosus Patients: a Paradigm Shift Based on the Experience of a Tertiary Referral Center
author Dias-Santos, A
author_facet Dias-Santos, A
Ferreira, J
Pinheiro, S
Cunha, JP
Alves, M
Papoila, AL
Moraes-Fontes, MF
Proença, R
author_role author
author2 Ferreira, J
Pinheiro, S
Cunha, JP
Alves, M
Papoila, AL
Moraes-Fontes, MF
Proença, R
author2_role author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Repositório do Centro Hospitalar Universitário de Lisboa Central, EPE
dc.contributor.author.fl_str_mv Dias-Santos, A
Ferreira, J
Pinheiro, S
Cunha, JP
Alves, M
Papoila, AL
Moraes-Fontes, MF
Proença, R
dc.subject.por.fl_str_mv CHLC OFT
HSAC DAUTOIM
HCC DAUTOIM
CHLC CINV
Adult
Female
Male
Humans
Antirheumatic Agents / adverse effects
Drug-Related Side Effects and Adverse Reactions / diagnosis
Drug-Related Side Effects and Adverse Reactions / etiology
Eye Diseases / diagnosis
Eye Diseases / etiology
Hydroxychloroquine / adverse effects
Lupus Erythematosus, Systemic / complications*
Lupus Erythematosus, Systemic / diagnosis
Middle Aged
Prevalence
Prospective Studies
Retinal Diseases / chemically induced
Retinal Diseases / diagnosis
Tertiary Care Centers
Tomography, Optical Coherence
Visual Acuity
topic CHLC OFT
HSAC DAUTOIM
HCC DAUTOIM
CHLC CINV
Adult
Female
Male
Humans
Antirheumatic Agents / adverse effects
Drug-Related Side Effects and Adverse Reactions / diagnosis
Drug-Related Side Effects and Adverse Reactions / etiology
Eye Diseases / diagnosis
Eye Diseases / etiology
Hydroxychloroquine / adverse effects
Lupus Erythematosus, Systemic / complications*
Lupus Erythematosus, Systemic / diagnosis
Middle Aged
Prevalence
Prospective Studies
Retinal Diseases / chemically induced
Retinal Diseases / diagnosis
Tertiary Care Centers
Tomography, Optical Coherence
Visual Acuity
description Objective: To evaluate ocular involvement in a cohort of systemic lupus erythematosus (SLE) patients of a tertiary referral center and to compare the results with the existing literature. Methods: Patients underwent a complete ophthalmological evaluation, including visual acuity, slit-lamp examination, fluorescein staining, Schirmer-I test, Goldmann applanation tonometry, fundoscopy, 10-2 automated threshold visual fields, fundus autofluorescence and spectral-domain optical coherence tomography to screen for hydroxychloroquine (HCQ) macular toxicity. Results: A total of 161 patients (16 men and 145 women) were enrolled in this study. The mean age was 47.6 years and the mean disease duration was 11.5 years. Fifty patients (31.1%) had at least one ocular manifestation of SLE. The most frequent manifestation was dry eye syndrome (12.4%), immediately followed by cataracts (11.2%) and HCQ macular toxicity (11.2%). Among patients with HCQ maculopathy, two presented with an atypical spectral-domain optical coherence tomography pattern. Five patients (3.1%) presented with glaucoma, two patients (1.2%) presented with SLE retinopathy while only one presented with lupus choroidopathy (0.6%). Conclusions: Compared with previous studies, we conclude there has been a significant reduction in disease-related ocular complications, particularly those associated with poor systemic disease control. On the other hand, drug and age-related complications are assuming a prominent role in the ophthalmic care of these patients.
publishDate 2020
dc.date.none.fl_str_mv 2020-03
2020-03-01T00:00:00Z
2021-11-23T15:12:01Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.17/3915
url http://hdl.handle.net/10400.17/3915
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Lupus. 2020 Mar;29(3):283-289.
10.1177/0961203320903080.
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Sage
publisher.none.fl_str_mv Sage
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799131308408963072